New combo aims to outsmart prostate cancer without Long-Term hormone shots

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) — alone or with an injected immune stimulant called SD-101 — to standard radiation and short-term hormone therapy could better control prostate cancer that has spread to a few spots. Twenty-three men with newly diagnosed, hormone-sensitive prostate cancer took part. The goal was to see if the combination could keep PSA levels low even after hormone therapy was stopped, potentially allowing men to avoid continuous hormone treatment.